BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17047198)

  • 1. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
    Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
    J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
    Hubner RA; Muir KR; Liu JF; Logan RF; Grainge MJ; Houlston RS;
    Clin Cancer Res; 2008 Apr; 14(8):2303-9. PubMed ID: 18413818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
    Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
    Cole BF; Baron JA; Sandler RS; Haile RW; Ahnen DJ; Bresalier RS; McKeown-Eyssen G; Summers RW; Rothstein RI; Burke CA; Snover DC; Church TR; Allen JI; Robertson DJ; Beck GJ; Bond JH; Byers T; Mandel JS; Mott LA; Pearson LH; Barry EL; Rees JR; Marcon N; Saibil F; Ueland PM; Greenberg ER;
    JAMA; 2007 Jun; 297(21):2351-9. PubMed ID: 17551129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
    Martinez ME; O'Brien TG; Fultz KE; Babbar N; Yerushalmi H; Qu N; Guo Y; Boorman D; Einspahr J; Alberts DS; Gerner EW
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7859-64. PubMed ID: 12810952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
    Barry EL; Mott LA; Sandler RS; Ahnen DJ; Baron JA
    Cancer Prev Res (Phila); 2011 Dec; 4(12):2072-82. PubMed ID: 21930798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
    Figueiredo JC; Levine AJ; Grau MV; Midttun O; Ueland PM; Ahnen DJ; Barry EL; Tsang S; Munroe D; Ali I; Haile RW; Sandler RS; Baron JA
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2136-45. PubMed ID: 18708408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
    Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
    J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
    Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
    J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial.
    Grau MV; Baron JA; Sandler RS; Wallace K; Haile RW; Church TR; Beck GJ; Summers RW; Barry EL; Cole BF; Snover DC; Rothstein R; Mandel JS
    J Natl Cancer Inst; 2007 Jan; 99(2):129-36. PubMed ID: 17227996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial.
    Barry EL; Peacock JL; Rees JR; Bostick RM; Robertson DJ; Bresalier RS; Baron JA
    JAMA Oncol; 2017 May; 3(5):628-635. PubMed ID: 27978548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
    Barry EL; Poole EM; Baron JA; Makar KW; Mott LA; Sandler RS; Ahnen DJ; Bresalier RS; McKeown-Eyssen GE; Ulrich CM
    Cancer Causes Control; 2013 Jan; 24(1):47-54. PubMed ID: 23081681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.
    Grau MV; Baron JA; Barry EL; Sandler RS; Haile RW; Mandel JS; Cole BF
    Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2353-8. PubMed ID: 16214916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence.
    Hubner RA; Muir KR; Liu JF; Logan RF; Grainge MJ; Houlston RS;
    Int J Cancer; 2008 Aug; 123(3):586-93. PubMed ID: 18470879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).
    Fedirko V; Bradshaw PT; Figueiredo JC; Sandler RS; Barry EL; Ahnen DJ; Milne GL; Bresalier RS; Baron JA
    Cancer Prev Res (Phila); 2015 Nov; 8(11):1061-8. PubMed ID: 26304466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
    Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
    J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
    Grau MV; Sandler RS; McKeown-Eyssen G; Bresalier RS; Haile RW; Barry EL; Ahnen DJ; Gui J; Summers RW; Baron JA
    J Natl Cancer Inst; 2009 Feb; 101(4):267-76. PubMed ID: 19211442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation.
    Levine AJ; Grau MV; Mott LA; Ueland PM; Baron JA
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2541-8. PubMed ID: 20841390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
    Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
    Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.